Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Selcia, a UK based contract research firm, has entered into a research pact with Sweden-based NeuroVive Pharmaceutical to develop new drugs compounds and medicines for mitochondrial physiology and pathophysiology.
Subscribe to our email newsletter
Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine.
NeuroVive CEO Mikael Bronnegard said in this collaboration with Selcia, NeuroVive will target the development of new drugs for diseases like stroke, heart attack, obesity, and cancer – all large potential markets with significant burden of disease.
"This will add new drug entities to NeuroVive’s broad development pipeline and will enable the company to capitalize on the commercial opportunities deriving from our expertise in mitochondrial research, including our cyclophilin-D program," Bronnegard said.
NeuroVive CSO Eskil Elmer said this collaboration with Selcia will allow them to accelerate the discovery and development of new mitochondrial medicines and drug-like compounds within the scope of their current R&D budget in the discovery phase.